marked.bio

IDH1/2 inhibitor · small molecule

HMPL-306

2 active trials, targeting IDH1/2. Not approved for any biomarker on marked.bio yet.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
IDH1/2 mutation 2 5 Phase 3

Sponsors

Industry sponsors leading active biomarker-selected trials of HMPL-306.

  1. HUTCHMED 2

Trials

2 of 5 trials shown

  1. A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia

    Recruiting Phase 3 HUTCHMED Started 2024Primary completion 2028-12 NCT06387069

    HMPL-306Salvage Chemotherapy Regimen

    Cohort 1: Patients with R/R primary AML harboring IDH1-R132 site mutation \[WHO 2022 Classification Criteria for Myeloid Neoplasms and Acute Leukemia…

    IDH1/2 mutationAcute Myeloid Leukemia

  2. Phase I Study of HMPL-306 for the Treatment of Gliomas With IDH1 and/or IDH2 Mutations

    Recruiting Phase 1 HUTCHMED Started 2025Primary completion 2026-12 NCT07025018

    HMPL-306

    Safety Lead-In Phase: Patients with gliomas of a documented IDH1 and/or IDH2 mutation.

    IDH1/2 mutationGliomas Harboring IDH1 and/or IDH2 Mutations